HOPHF Stock - Hemogenyx Pharmaceuticals Plc
Unlock GoAI Insights for HOPHF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-799,809 | N/A | $-2,599,762 | $-283,647 | $-350,719 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-7,164,666 | $-6,465.846 | $4.00M | $-2,702,754 | $-2,150,386 |
| Net Income | $-5,619,181 | $-6,690.678 | $-3,979,314 | $-5,099,228 | $-2,082,220 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.13 | $-2.37 | $-1.62 | $-2.64 | $-2.01 |
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Visit WebsiteEarnings History & Surprises
HOPHFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q3 2025 | Sep 25, 2025 | — | $-2.66 | — | — |
Q2 2025 | Apr 28, 2025 | — | — | — | — |
Q3 2024 | Sep 27, 2024 | — | $-1.16 | — | — |
Q2 2024 | Apr 25, 2024 | — | $-0.99 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-2.10 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-1430.92 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-558.86 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-791.16 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-3671.19 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-1569.10 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-1047.18 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-1055.83 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-994.68 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-1.34 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.94 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-4.10 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.31 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.50 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.55 | — | — |
Latest News
Frequently Asked Questions about HOPHF
What is HOPHF's current stock price?
What is the analyst price target for HOPHF?
What sector is Hemogenyx Pharmaceuticals Plc in?
What is HOPHF's market cap?
Does HOPHF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HOPHF for comparison